The risk of developing bile duct cancer, also known as cholangiocarcinoma, is almost doubled for type 2 diabetics using one of the following diabetes medicines:
Janumet (sitagliptin / metformin HCl)
Kombiglyze XR (saxagliptin and metformin)
Qtern (dapagliflozin and saxagliptin)
Kazano (alogliptin and metformin)
Oseni (alogliptin and pioglitazone)
Jentadueto (linagliptin and metformin HCl)
Glyxambi (empagliflozin / linagliptin)
These diabetes medicines are in the dipeptidyl peptidase-4 (DPP-4) inhibitor drug class.
In more detail, a BMJ article, “Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study”, published in December 2018, reports on a medical study whihch showed that the use of DPP-4 inhibitors diabetes drugs was associated with a near doubling of the risk of bile duct cancer.
This December 2018 BMJ medical journal article concluded with an important call-to-action:
Given the high fatality rate of this cancer, post hoc analyses of randomised controlled trials and additional observational studies are needed to corroborate our findings.
We will continue to monitor the medical literature for more about bile duct cancer being a possible side effect of DPP-4 inhibitor diabetes drugs.[Read article in full at original source]